U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H18N4O
Molecular Weight 330.3839
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PKI-166

SMILES

C[C@]([H])(c1ccccc1)N=c2c3cc(-c4ccc(cc4)O)[nH]c3[nH]cn2

InChI

InChIKey=XRYJULCDUUATMC-CYBMUJFWSA-N
InChI=1S/C20H18N4O/c1-13(14-5-3-2-4-6-14)23-19-17-11-18(24-20(17)22-12-21-19)15-7-9-16(25)10-8-15/h2-13,25H,1H3,(H2,21,22,23,24)/t13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H18N4O
Molecular Weight 330.3839
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16203782 | http://en.pharmacodia.com/web/drug/1_14094.html | https://www.ncbi.nlm.nih.gov/pubmed/23528611

PKI166 is a potent and selective EGFR kinase inhibitor (IC50 = 0.7 nM). PKI166 was tested in phase I clinical trials in patients with advanced solid malignancies, where the recommended dose for further studies was 750 mg once daily for 2 weeks every 4 weeks. In preclinical model, PKI166 was tested in pancreatic, prostate, renal cell, colorectal and other types of cancer. The development of PKI166 was discontinued in 2002 after phase II clinical trials. PKI166 possess antihypertensive properties demonstrated in rat hypertensive chronic kidney disease model.

Originator

Curator's Comment:: # Novartis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00533|||Q9GZX1
Gene ID: 1956.0
Gene Symbol: EGFR
Target Organism: Homo sapiens (Human)
0.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1319 ng/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2159 ng/mL
900 mg 1 times / day steady-state, oral
dose: 900 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
273 ng/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
403 ng/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13727 ng × h/mL
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18853 ng × h/mL
900 mg 1 times / day steady-state, oral
dose: 900 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3334 ng × h/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3555 ng × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.1 h
750 mg 1 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.2 h
900 mg 1 times / day steady-state, oral
dose: 900 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.2 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PKI-166 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
DLT: rash, diarrhea...
Other AEs: Fatigue, Anorexia...
Dose limiting toxicities:
rash (grade 3, 1 pt)
diarrhea (grade 3, 1 pt)
Alanine aminotransferase increase (grade 3, 1 pt)
Other AEs:
Fatigue (grades 3-4, 1 pt)
Anorexia (grade 1-2, 2 patients)
Nausea (grade 1-2, 4 patients)
Vomiting (grade 1-2, 3 patients)
Aspartate aminotransferase increase (grade 1-2, 1 pt)
Sources:
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Other AEs: Myalgia, Alanine aminotransferase increase...
Other AEs:
Myalgia (grade 3-4, 1 pt)
Alanine aminotransferase increase (grade 3-4, 1 pt)
abdominal pain (grade 1-2, 3 patients)
Fatigue (grade 1-2, 1 pt)
Diarrhea (grade 1-2, 11 patient)
Rash (grade 1-2, 5 patients)
Nausea (grade 1-2, 7 patients)
vomiting (grade 1-2, 6 patients)
Anorexia (grade 1-2, 1 pt)
Aspartate aminotransferase increase (grade 1-2, 4 patients)
Dry mouth (grade 1-2, 2 patients)
Sources:
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
DLT: Alanine aminotransferase increase...
Other AEs: Nausea, Vomiting...
Dose limiting toxicities:
Alanine aminotransferase increase (grade 3, 2 patients)
Other AEs:
Nausea (grade 1-2, 4 patients)
Vomiting (grade 1-2, 3 patients)
Anorexia (grade 1-2, 1 pt)
Diarrhea (grade 1-2, 2 patients)
Rash (grade 1-2, 1 pt)
Aspartate aminotransferase increase (grade 1-2, 3 patients)
Fatigue (grade 1-2, 3 patients)
Sources:
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
DLT: Alanine aminotransferase increase, Aspartate aminotransferase increase...
Other AEs: Abdominal pain, vomiting...
Dose limiting toxicities:
Alanine aminotransferase increase (grade 3, 1 pt)
Aspartate aminotransferase increase (grade 3, 2 patients)
Other AEs:
Abdominal pain (grade 1-2, 1 pt)
vomiting (grade 1-2, 3 patients)
Nausea (grade 1-2, 5 patients)
Rash (grade 3-4, 1 pt)
Anorexia (grade 1-2, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Aspartate aminotransferase increase grade 1-2, 1 pt
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Anorexia grade 1-2, 2 patients
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Vomiting grade 1-2, 3 patients
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Nausea grade 1-2, 4 patients
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Alanine aminotransferase increase grade 3, 1 pt
DLT
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
diarrhea grade 3, 1 pt
DLT
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
rash grade 3, 1 pt
DLT
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Fatigue grades 3-4, 1 pt
900 mg 1 times / day multiple, oral (unknown)
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 5
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 5
Sources:
Anorexia grade 1-2, 1 pt
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Fatigue grade 1-2, 1 pt
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Diarrhea grade 1-2, 11 patient
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Dry mouth grade 1-2, 2 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
abdominal pain grade 1-2, 3 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Aspartate aminotransferase increase grade 1-2, 4 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Rash grade 1-2, 5 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
vomiting grade 1-2, 6 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Nausea grade 1-2, 7 patients
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Alanine aminotransferase increase grade 3-4, 1 pt
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Myalgia grade 3-4, 1 pt
750 mg 1 times / day multiple, oral (unknown)
MTD
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 13
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources:
Anorexia grade 1-2, 1 pt
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Rash grade 1-2, 1 pt
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Diarrhea grade 1-2, 2 patients
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Aspartate aminotransferase increase grade 1-2, 3 patients
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Fatigue grade 1-2, 3 patients
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Vomiting grade 1-2, 3 patients
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Nausea grade 1-2, 4 patients
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Alanine aminotransferase increase grade 3, 2 patients
DLT
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Abdominal pain grade 1-2, 1 pt
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Anorexia grade 1-2, 2 patients
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
vomiting grade 1-2, 3 patients
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Nausea grade 1-2, 5 patients
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Alanine aminotransferase increase grade 3, 1 pt
DLT
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Aspartate aminotransferase increase grade 3, 2 patients
DLT
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Rash grade 3-4, 1 pt
50 mg 1 times / day multiple, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
PubMed

PubMed

TitleDatePubMed
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
2000 Jun 1
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
2005 Oct 1
Patents

Patents

Sample Use Guides

In phase I clinical trials in patients with advanced solid malignancies, PKI166 was first given orally once daily continuously and in the second part of the study once daily for 2 weeks every 4 weeks to establish the maximum tolerated dose. The recommended dose for further studies was 750 mg once daily for 2 weeks every 4 weeks.
Route of Administration: Oral
In vitro enzyme assays using EGF-R protein tyrosine kinase was performed in 96-well plates as a filter binding assay. The rate of kinase reaction was measured by a transfer of [γ-33P]ATP to a substrate. PKI166 inhibits EGFR with IC50 of 0.7 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:57:39 UTC 2021
Edited
by admin
on Fri Jun 25 23:57:39 UTC 2021
Record UNII
9RIE5HW38P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PKI-166
Common Name English
CGP-75166
Code English
PKI 166 [WHO-DD]
Common Name English
4-(4-((1-PHENYLETHYL)AMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-6-YL)-PHENOL, R-
Common Name English
NVP-PKI166
Code English
Code System Code Type Description
PUBCHEM
6918403
Created by admin on Fri Jun 25 23:57:40 UTC 2021 , Edited by admin on Fri Jun 25 23:57:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL1963502
Created by admin on Fri Jun 25 23:57:40 UTC 2021 , Edited by admin on Fri Jun 25 23:57:40 UTC 2021
PRIMARY
CAS
187724-61-4
Created by admin on Fri Jun 25 23:57:40 UTC 2021 , Edited by admin on Fri Jun 25 23:57:40 UTC 2021
PRIMARY
FDA UNII
9RIE5HW38P
Created by admin on Fri Jun 25 23:57:40 UTC 2021 , Edited by admin on Fri Jun 25 23:57:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY